Global Lower GI Series Market Research Report- Forecast till 2027

Lower GI Series Market Information: By Applications (Gastroenteritis, Colon Polyps, Tumor, Strictures Crohn's Disease, Ulcerative Colitis and others), By Test Types (Double-Contrast and Single-Contrast) and By End Users (Hospitals, Clinics & Laboratories) - Global Forecast till 2027

ID: MRFR/Pharma/0287-HCR | February 2021 | Region: Global | 105 Pages         

Table of Contents

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.2 Restraints

5 Market Factor Analysis

5.1 Porter’s Five Forces Model

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Supply Chain Analysis

6. Global Lower GI Series Market, by Applications

6.1 Gastroenteritis

6.2 Colon polyps

6.3 Tumor

6.4 Strictures Crohn's disease

6.5 Ulcerative colitis

6.6 Others

7. Global Lower GI Series Market, by Type of Test

7.1 Double-contrast

7.2 Single-contrast

8 Global Lower GI Series Market, by End Users

8.1 Hospitals

8.2 Clinics & laboratories

9. Global Point of Care Technology Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 UK

9.3.1.3 France

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of Middle East & Africa

10 Competitive Landscape

10.1 Cost of Products

10.2 Production Capacity of Major Players

11 Company Profile

11.1 Eisai (US)

11.1.1 Overview

11.1.2 Product/Business Segment Overview

11.1.3 Financial Updates

11.1.4 Key Developments

11.2 Cadila Pharmaceuticals

11.2.1 Overview

11.2.2 Product/Business Segment Overview

11.2.3 Financial Updates

11.2.4 Key Developments

11.3 Purdue Pharma L.P

11.3.1 Overview

11.3.2 Product/Business Segment Overview

11.3.3 Financial Updates

11.3.4 Key Development

11.4 PeaceHealth

11.4.1 Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Updates

11.4.4 Key Development

11.5 Alfa Wassermann

11.5.1 Overview

11.5.2 Product/Business Segment Overview

11.5.3 Financial Updates

11.5.4 Key Developments

11.6 NOVADAQ

11.6.1 Overview

11.6.2 Product/Business Segment Overview

11.6.3 Financial Updates

11.6.4 Key Developments

11.7 AstraZeneca

11.7.1 Overview

11.7.2 Product/Business Segment Overview

11.7.3 Financial Updates

11.7.4 Key Developments

11.8 Ironwood Pharmaceuticals

11.8.1 Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financial Updates

11.8.4 Key Developments

11.9 Others

11.9.1 Overview

11.9.2 Product/Business Segment Overview

11.9.3 Financial Updates

11.9.4 Key Developments

12 Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Gastro-care Industry

13 Appendix

Lower GI Series Market Speak to Analyst Request a Free Sample

Lower GI Series Market Overview 

Lower GI series is a lower gastrointestinal series or barium enema; it is one of the medical procedure, which helps in diagnosis of diseases and abnormalities related to human large intestine and rectum. Moreover, major companies are focusing on investment in R&D to introduce efficient methods as well as innovative devices since they are under constant pressure to provide new and cost-effective methods.


According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 60-70 million people are affected by either major or minor GIT diseases in America. The number is continuously increasing due to poor diet and increasing aging population. The lower GI series market is driven majorly due to increasing prevalence of GI diseases, gastric cancer, and changing lifestyle. Additionally, developing technologies, increasing cost-effective methods, and the government’s support for research have boosted the growth of this market. However, availability of alternative therapies may hamper the growth of the market during the review period.


The lower GI series market is expected to grow at a CAGR of 4.6% during the forecast period 2017-2023.

FIGURE 1 Lower GI Series Market, by Applications, 2016 (%) Lower GI Series Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Segments                                                       

The lower GI series market is segmented on the basis of by applications, types of tests, and end user.


On the basis of applications, it is segmented into gastroenteritis, colon polyps, tumor, strictures crohn's disease, ulcerative colitis, and others.


On the basis of types of test, it is segmented into double-contrast test and single-contrast test.


On the basis of end users, this market is segmented into hospitals, clinics, and laboratories.


 Research Methodology


Lower GI Series Market-

Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Regional Analysis of the Lower GI Series Market 

On the regional basis, the market is segmented into the America, Europe, Asia Pacific, and the Middle East & Africa. The America owns a significant share in the global market as a result of huge investment in research and development in the healthcare sector and its strong economic conditions for research and development. Increasing patient base and geriatric population to boost the growth of the Lower GI Series Market


Europe is the second largest market followed by Asia Pacific on account of increasing technological improvements. The technological improvements will result in higher efficiency and accuracy for diagnosis. Asia Pacific is the fastest growing market due to increasing prevalence of communicable diseases in this region. India and China have started investing in research and development of healthcare sector, which will boost the Lower GI Series Market growth of this region.


Key Players in the Lower GI Series Market                                         

Some of the key players in Lower GI Series Market are Eisai (US), Cadila Pharmaceuticals, PeaceHealth, Purdue Pharma L.P., Alfa Wassermann, NOVADAQ, Mount Sinai Beth Israel, AstraZeneca, and Ironwood Pharmaceuticals Inc.      

Intended Audience



  • Manufacturing industries

  • Pharmaceutical industry

  • Biotechnology companies

  • Research and development (R&D) companies

  • Government research laboratories

  • Medical research institutes



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The low GI series market CAGR is 4.6% during the forecast period.

The availability of alternative therapies can prevent low GI series market growth.

The Americas is in charge of the low GI series market.

The low GI series market end users are hospitals, clinics, and laboratories.

The low GI series market report has gastroenteritis, colon polyps, tumor, strictures Crohn's disease, ulcerative colitis, and others.